🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Shanghai Minwei Biotechnology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and Australia registers with Shanghai Minwei Biotechnology as lead sponsor. Synced 27 Sep 2026
12Current trials
6Recruiting now
5Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Shanghai Minwei Biotechnology is the lead sponsor of 12 current clinical trials in our China and Australia registers. 6 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are MWN109 1, MWN109 2 and MWN109 3. The most-studied condition is Overweight , Obesity.

ClinicalTrials.gov trials by status

  • Recruiting650%
  • Not yet open325%
  • Active, closed325%

Trials by phase

  • Phase 1758%
  • Phase 2433%
  • Phase 318%
01

Clinical trials sponsored by Shanghai Minwei Biotechnology

12 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemia
NCT07803822 · ClinicalTrials.gov ↗ · Mixed Dyslipidemia
Phase 2 Recruiting 2026-09 China
A Study to Evaluate MWN109 Injection in Healthy Subjects
NCT06859853 · ClinicalTrials.gov ↗ · Overweight or Obese
Phase 1 Recruiting 2025-03 Australia
A Study to Evaluate MWN109 Tablets in Healthy Adult Participants
NCT06938269 · ClinicalTrials.gov ↗ · Overweight or Obesity
Phase 1 Recruiting 2025-06 Australia
Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild Hypertension
NCT07803835 · ClinicalTrials.gov ↗ · Essential Hypertension, Healthy Volunteers
Phase 1 Recruiting 2026-03 China
Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus
NCT07801820 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus (T2DM)
Phase 2 Recruiting 2026-06 China
Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
NCT07803809 · ClinicalTrials.gov ↗ · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
Phase 1 Recruiting 2026-04 China
Phase 1 Clinical Study of MWN110 Injection in Healthy Participants and Overweight or Obese Participants
NCT07779980 · ClinicalTrials.gov ↗ · Overweight , Obesity
Phase 1 Not yet open 2026-08 China
Phase 1 Clinical Study of MWN117 Injection in Healthy Participants and Participants With Obesity
NCT07824804 · ClinicalTrials.gov ↗ · Healthy Volunteers, Obesity
Phase 1 Not yet open 2026-09 China
Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity
NCT07778693 · ClinicalTrials.gov ↗ · Overweight , Obesity
Phase 3 Not yet open 2026-09 China
Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight
NCT07791537 · ClinicalTrials.gov ↗ · Overweight , Obesity
Phase 2 Active, closed 2025-12 China
Phase 1 Clinical Study of MWX203 Injection in Healthy Subjects
NCT07799025 · ClinicalTrials.gov ↗ · Healthy Volunteers
Phase 1 Active, closed 2025-07 China
Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity
NCT07804797 · ClinicalTrials.gov ↗ · Overweight , Obesity
Phase 2 Active, closed 2026-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Shanghai Minwei Biotechnology trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Shanghai Minwei Biotechnology trials

9 conditions
Overweight , Obesity5Healthy Volunteers3Type 2 Diabetes Mellitus (T2DM)2Mixed Dyslipidemia1Essential Hypertension1Obesity1MASH - Metabolic Dysfunction-Associated Steatohepatitis1Overweight or Obese1Overweight or Obesity1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China104
Clinical trials in Australia22

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Overweight , Obesity

SponsorTrials
Beijing QL Biopharmaceutical3
Moon (Guangzhou) Biotechnology1

Sponsors with the most current trials registered for this condition.

06

Questions about Shanghai Minwei Biotechnology trials

How many clinical trials does Shanghai Minwei Biotechnology sponsor?

Shanghai Minwei Biotechnology is the lead sponsor of 12 current trials on ClinicalTrials.gov in our China and Australia registers, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai Minwei Biotechnology trials recruiting?

Yes. 6 of its 12 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai Minwei Biotechnology testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are MWN109 1 (4), MWN109 2 (4), MWN109 3 (3), Inclisiran sodium (1) and Semaglutide (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.